Home Blog Page 6

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

0

MMS, an award-winning, data-focused clinical research organization (CRO), announced today its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland. The acquisition will add the company’s flagship product, KerusCloud®, a state-of-the-art, cloud-based statistical modeling and simulation platform to MMS’ data-driven approach towards efficient drug development.

With a history of strong organic growth, the acquisition of Exploristics positions MMS to enhance its global footprint and capabilities in advanced clinical trial design, innovative statistics, and data science. Building on its excellent track record in regulatory and end-game submissions, this acquisition now solidifies MMS as the leader in biometrics and development strategy solutions for biotechnology and pharmaceutical sponsors of all sizes.

“We are proud to bring the Exploristics team into the #OneMMS family,” said Dr. Uma Sharma, CEO, MMS. “When exploring acquisition opportunities to enhance our strategic capabilities as a leading data CRO, we sought organizations that would complement our existing regulatory approach and build a powerful combination of regulatory and statistical design expertise, combined with market-leading study simulation software. We found that in Exploristics, along with a like-minded culture.”

Chris Schoonmaker, Chief Operating Officer at MMS, added, “Exploristics joining MMS is an exceptional fit, and we look forward to delivering even greater value to our clients through optimized strategies that reduce the overall time and cost burden in drug development.”

Expanding Expertise and Global Reach in Europe

The acquisition of Exploristics by MMS aligns with the company’s focus on broadening its data-focused solutions to enhance the ability to simulate, analyze, and optimize studies, as well as reduce risk and drive efficiencies. By combining the two organizations’ strengths, MMS will now provide:

  • Advanced statistical design and data science capabilities across diverse therapeutic areas and study types.
  • Enhanced and real-time pivots for orphan, rare, and special disease populations with an unmet medical need.
  • Study simulation and development planning with the integration of KerusCloud into an existing award-winning technology suite that boasts a 3x increase in development program success rates and up to USD 20 million saved on a single study.
  • Expanded global presence, with increased scale in Europe and access to a highly skilled team of biostatisticians and data scientists.

“Joining MMS represents an exciting new chapter for Exploristics,” said Aiden Flynn, Founder and CEO of Exploristics, now Senior Vice President, Head of Strategic Statistical Consulting at MMS. “Our ethos has always centered on openness, honesty, professionalism, flexibility, and creativity—qualities that I’ve experienced at MMS since day one of our discussions. I am confident that our employees, partners, and clients will benefit from this partnership as we amplify our impact and expand our global reach.”

Ben Dudley, Chief Commercial Officer at MMS, added “Our presence in Europe has seen significant growth in recent years, and this acquisition adds to our vitality in the region. Our focus on data for better trial data execution, lower risk, stronger submissions, integration of Real-World Data (RWD) into clinical outputs and accelerated outcomes has never been stronger than it is today.”

Learn more about MMS at https://www.mmsholdings.com.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com

About Exploristics

Exploristics is a world-leading technology-enabled services company that transforms clinical development for life sciences organizations with unique proprietary software and biostatistics consultancy supporting the planning, design, and analysis of clinical studies.

About KerusCloud®

KerusCloud, an MMS technology, is a revolutionary simulation-guided study design tool that ensures clinical trials are designed effectively to collect the right data, in the right patients, in the right way. Its use supports evidence-based design decisions to extensively de-risk real clinical studies, reducing development times, costs, and patient burden.

Flow Secures First Wholesale Insurance AI Agent to Pass RPLU Exams

0

Flow Specialty, the wholesale 3.0 specialty commercial brokerage, is announcing the industry’s first AI insurance broker. The brokerage’s Platformless AI model has passed RPLU certification exams for the Cyber, Errors & Omissions, and Executive liability modules. By attaining this level of rigor, Flow’s expert brokers have real leverage: AI agents who can take meaningful work off brokers’ plates. This milestone celebrates the ability to scale access to expertise — a capability that completely changes the specialty commercial insurance market dynamics.  

Historically, the small and medium business segments across all industries have struggled to find comprehensive coverage that enables them to transfer risk confidently. This is because crafting commercial policies demands the expertise and time of brokers. However, brokers, who are there to deliver expertise on tailoring individual policies based on unique business needs, are only compensated for quotes that bind (about one in four quotes). This compensation structure means traditional brokers focus on large enterprises that yield lucrative commission dollars. Meanwhile, small and medium businesses are left exposed.

“For far too long, the middle market segment of specialty business has been underserved for retail brokers. I have been in this industry for more than two decades and have observed an underperformance around the quality of service, attention to details, and ability to serve the client in a manner they deserve. The stumbling blocks for wholesalers have been thin margins, bandwidth issues, and inconsistency of expertise across teams. We have solved these problems by using AI to dramatically scale our human brokers abilities far beyond what has been previously possible,” shares David Derigiotis, President of Brokerage and Head of Insurance.

Flow is building an ecosystem of AI agents who operate like the world’s best assistants. Based on the GPT 4.0 Omni core, Flow’s AI agents are trained on an ever-growing library of insurance materials—specimens, quotes, and carrier risk appetites—and the ongoing transaction of endless communication materials and critical decision points. Flow’s AI agents know not only materials but also understand tradeoffs and considerations. 

Flow’s hybrid approach to human brokers supported by AI agents goes beyond mere data problem-solving. By digitizing knowledge, Flow’s internal workflow engine enables AI models to cross-reference materials, learn from broker interactions, and evolve continuously. These AI Agents are integral team members, handling labor-intensive tasks such as risk appetite matching, generating quote comparisons, and constructing review materials. Flow brokers are always in the loop, revising and overseeing the output of this workflow engine. This approach of experts supported by AI agents reduces the manual investment required by individual brokers and makes it possible to deliver an expert-rich experience for every premium. 

“In an industry that runs on trust and relationships, like the commercial insurance space, scale is a real issue. How do you enable brokers to take on more workload without burning the bridges of trust?  The key is to enable wholesale brokers with ultimate availability, every single time. And in order for our brokers to provide this level of service, we’re training our AI to operate as the world’s best assistant,” said CEO and Founder, Sivan Iram.

Learn more at www.flowspecialty.com

Renowned Business Leader Klaus Kleinfeld Unveils New Book “Leading to Thrive”

Klaus Kleinfeld, renowned business leader and former CEO of Siemens and Alcoa, today announced the release of his highly anticipated book, “Leading to Thrive: Mastering Strategies for Sustainable Success in Business and Life.” Success in both your business and personal lives is possible. You don’t have to choose one over the other. Leading to Thrive shows you how.

Klaus Kleinfeld draws on decades of global business experience from large scale to startups across a wide range of industries. He reveals how to win both the Outer Game of business success and the Inner Game of personal fulfillment.

Leading to Thrive charts a transformative path for building an inspiring vision, creating competitive advantages, and motivating world-class teams. Then, it goes deeper, exploring how to preserve and recover your energy, achieve balance, and find true purpose and meaning.

Filled with real-world advice from one of the world’s most experienced business practitioners, Leading to Thrive is a must-read for every business leader aiming for sustained success in business and in life.

“Success in business requires more than just hard work; it demands a holistic approach that integrates both personal well-being and organizational performance,” said Kleinfeld. “With this new book, I want to provide a roadmap for the leaders of today and tomorrow to help in navigating their journeys with both purpose and balance.”

Understanding the inner game versus the outer game

The Inner Game emphasizes the importance of effectively managing physical, emotional, mental, and spiritual energy as foundational elements for sustainable success in both business and life. It focuses on unlocking one’s inner strengths, creating resilience, and finding purpose.

Understanding these fundamentals enable leaders to enhance their performance, maintain balance, and navigate the challenges of today’s fast-paced environment. It allows them to fuel long-term growth and fulfillment.

The increased inner strength unlocks success in whichever Outer Game a leader chooses to engage. Within the text, Kleinfeld emphasizes common challenges like defining a winning strategy, flawlessly executing, high-performance team dynamics, and effective board and stakeholder management. Leaders are guided on how to create inspiring visions, build sustainable competitive advantages, and cultivate a collaborative culture that drives collective success.

By integrating insights from the Inner Game, leaders will learn how to constantly recharge – even in very little time – and refuel their Outer Game. Kleinfeld also touches upon optimizing one’s leadership style and making truly informed decisions that align with their values, ultimately resulting in impactful outcomes for their organizations and the communities they serve.

Early praise for Leading to Thrive

For this new release, Kleinfeld has garnered significant praise from some of the most influential leaders in business, including:

  • “Klaus Kleinfeld has had an amazing career leading some of the world’s great companies. In Leading to Thrive, he shares lessons he learned along the way with profound insights for lasting success in business and in life.” – Marc Benioff, Co-founder, Chairman, and CEO of Salesforce
  • “This book reflects Klaus’s commitment to helping leaders achieve success with purpose and balance.” -Jay Y. Lee, Executive Chairman of Samsung
  • “Klaus’s insights are both practical and inspiring—perfect for leaders at any stage.” – Stephen A. Schwarzman, Chairman, CEO and Co-founder of Blackstone
  • “Klaus is a visionary who understands big-picture and minute details. He has managed to master business and well-being…a rare quality.” – Diane von Fürstenberg, fashion designer and Founder of the DVF brand
  • “Klaus weaves together the principles of conscious leadership and sustainable success, offering a blueprint for aligning business with the deeper currents of life.” – Dr. Deepak Chopra, Founder of the Chopra Foundation and Chopra Global
  • “In addition to his incredible life story, Klaus gives his readers a roadmap to success in their own journeys. A must-read for anyone hoping to excel and go further than they thought.” – Ken Langone, entrepreneur, investor, and Co-founder of Home Depot

Leading to Thrive is available for purchase on Amazon, and learn more at: https://www.leading-to-thrive.com/

About Klaus Kleinfeld

Dr. Klaus Kleinfeld is the only leader to have successfully served as CEO of two Fortune 500 giants on different continents: Alcoa in the US and Siemens in Germany. With a nearly forty-year career spanning multiple industries, from established businesses to tech startups, he has advised US presidents and global leaders across Europe, Asia, and the Middle East. As the founder of K2Elevation, he invests in North American and European tech and biotech firms. Actively engaged in private sector, public affairs, and cultural boards, Dr. Kleinfeld, a dual US and European citizen, enjoys work, life, and family near New York.

Learn more: https://www.leading-to-thrive.com/

PumasAI is Set to Revolutionize Pharmacometrics and Clinical Pharmacology with the Launch of AskPumas and DeepPumas

PumasAI, a science-first organization dedicated to empowering innovation in drug development, today announced the launch of two transformative products: AskPumas and DeepPumas. Representing the first-ever intersection of AI and biosimulation, these tools are engineered to redefine pharmacometrics, clinical pharmacology, and data science.

With unprecedented predictive capabilities and seamless user integration, AskPumas and DeepPumas are designed to bridge data gaps and streamline workflows across departments, paving the way for more efficient and insightful drug development solutions. 

DeepPumas Allows Hybrid Modeling for Rich, Patient-Specific Predictions

Now available for public use, DeepPumas is set to change the landscape of drug development and patient outcome predictions. This powerful tool combines mechanistic and data-driven modeling, allowing pharmaceutical industry professionals to utilize their scientific understanding of a system while leveraging machine learning to capture complex and previously unknown relationships in patient data.

DeepPumas delivers significant advantages by enabling collaboration between departments — particularly between pharmacometrics and data science teams — while enhancing the ability to extract insights from complex datasets.

Key benefits of DeepPumas include the following:

  • Enhanced Data Utilization: DeepPumas enhances prediction capabilities with effective use of patient data for personalized predictions. 
  • Faster Model Development: This tool accelerates the process of model development and hypothesis generation through its combined knowledge- and data-driven approach. 
  • Flexibility for Big and Small Data: DeepPumas is equipped to handle both large and small datasets, overcoming the limitations of purely mechanistic models. 
  • Realistic Clinical Simulations: The tool allows for the simulation of realistic clinical trial populations by learning the conditional distribution of complex patient responses. 
  • Comprehensive Outcome Predictions: DeepPumas takes machine learning beyond simple metrics by providing rich, individualized time courses of patient outcomes based on complex covariates. 

With DeepPumas, we are making scientific machine learning integrated with statistics more accessible to the pharmaceutical industry and extending it to address the specific challenges of longitudinal data at the same time,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “After proving itself in beta with real-world customers, this hybrid approach has opened new doors for patient-specific insights and therapeutic outcomes at PumasAI and it will do the same for those that engage with it.”  

AskPumas: Your AI “Asked and Answered” Industry Friend 

The AskPumas tool introduces a novel approach to utilizing Retrieval Augmented Generation (RAG) technology within the healthcare space. Pharmacometricians and clinical pharmacologists can now seamlessly access a wealth of curated and up-to-date resources with this tool while ensuring data privacy and relevance to specific needs. Designed for flexibility and ease of use, AskPumas provides a robust value-add for organizations seeking powerful AI-driven insights without compromising sensitive data.

Key features of AskPumas include the following:

  • Private and Secure Data Integration: AskPumas enables secure use of private data without it leaving the organization, ensuring maximum utility and security. 
  • Curated Knowledge Resources: Through its constantly updated, focused resource base, the tool provides more relevant answers than generic large language models (LLMs). 
  • Flexibility and Customization: Users can easily extend AskPumas by integrating private knowledge sources, making it highly customizable to meet specific business needs. 
  • Improved Accuracy: By focusing on reducing hallucinations and ensuring human verification of AI responses, AskPumas provides reliable, source-backed information. 

AskPumas is more than just an AI assistant; it’s like a trusted partner for tackling the toughest questions in our field,” said Dr. Ivaturi. “Created by pharmacometricians for pharmacometricians, it mirrors how we work while ensuring user data remains private and secure. This is a pivotal tool for professionals in complex pharmacometric environments, and we’re excited to see how far it will drive our industry forward. And this is only the beginning—with our upcoming Workflow Agents, users can expect productivity to double.” 

A Leap Forward in Scientific AI 

With DeepPumas and AskPumas, PumasAI is delivering on its promise of AI meets biosimulation, marking a monumental leap in scientific innovation. These groundbreaking tools, crafted by experts within PumasAI, set a new standard for advanced collaboration and insight-driven workflows across healthcare and pharmaceutical industries. As these tools integrate into the daily workflows of professionals worldwide, PumasAI stands at the forefront, not just keeping pace with the future of biosimulation— but creating it. 

AskPumas and DeepPumas will be available for preview during the American Conference on Pharmacometrics (ACoP) 2024 annual conference in Arizona this November. For more information about DeepPumas, AskPumas, and how these tools can revolutionize your organization’s approach to scientific modeling and AI integration, visit https://pumas.ai/our-products.

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company includes the Pumas® suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more.

For additional information, visit www.pumas.ai